Home > Insider Trading > Dr Reddys Laboratories Ltd > Profile

Dr Reddys Laboratories Ltd (RDY)

Market is closed

Get Email Alerts

Profile
Hedge Fund Holdings
Insider Purchases
Insider Sales
Institutional Holdings
13 D/G Filings
News

Get Email Alerts

Sector: Pharmaceutical Preparations

Insider Roster

Subramanian Sundar Madhu Munnirpallam, Global Head Of Quality and Pv, 2026-04-10
Rudolf Patrick Aghanian, Head - Europe Generics, 2026-04-01
Kantilal Milan Kalawadia, Ceo - North America, 2026-04-01

Subramanian Sundar Madhu Munnirpallam, Global Head Of Quality and Pv, 2026-04-10
Rudolf Patrick Aghanian, Head - Europe Generics, 2026-04-01
Kantilal Milan Kalawadia, Ceo - North America, 2026-04-01
Ramana Venkata Motupalli, Ceo - Global Generics, 2026-04-01
Erez Israeli, Chief Executive Officer, 2026-04-01
Krishna Venkatesh, Global Head - Ipdo, 2026-04-01
Sushrut Kulkarni, Global Head - Ipdo, 2026-04-01
Phanimitra Srinivasa Bhethanabottla, Chief Information Officer, 2026-04-01
Narasimham Venkata Mannam, Chief Financial Officer, 2026-04-01
Deepak Sapra, Ceo - Api and Services, 2026-04-01
Alpna Seth, Director, 2026-04-01
Sanjaya Shikha Sharma, Director, 2026-03-27
Soshil Sanjiv Mehta, Director, 2026-03-27
Chan Penny Wan, Director, 2026-03-27
Krishnan Haran Pranatharthi Kodumudi, Director, 2026-03-27
Leo Puri, Director, 2026-03-27
Madhavan Arun Kumar, Director, 2026-03-27
Satish K Reddy, Director, 2026-03-20
V G Prasad, Director, 2026-03-20

Show All Insiders (19)

Hedge Fund Popularity

Display

13F filing is ongoing

Display Share Price

Display Large Version

Hedge Fund Holdings

Filing Period:

Last updated on September 22, 2026, 10:08am based on SEC 13F filings Last update: September 22, 2026, 10:08am

No.	Hedge Fund	Shares	Value	Activity	% Port
1.	Renaissance Technologies Jim Simons	7,347,028	$106,458,436	-7%	0.15%
2.	Marshall Wace LLP Paul Marshall And Ian Wace	2,025,356	$29,347,409	-24%	0.02%
3.	Quantinno Capital Hoon Kim	642,486	$9,309,636	+1%	0.01%
4.	AQR Capital Management Cliff Asness	552,705	$8,008,701	+25%	0%
5.	Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell	489,102	$7,087,088	+377%	0%

Institutional Investors' Holdings

Filing Period: Filing is Ongoing

No.	Name	Shares	Value	% Port
1.	Confluence Investment Management Llc	18,274	$230,618	0%
2.	Farther Finance Advisors, Llc	10,882	$137,334	0%
3.	Gamma Investing Llc	6,079	$76,717	0%
4.	Trust Co	82	$1,035	0%
5.	Versant Capital Management, Inc	58	$732	0%

News See All

Dr. Reddy's Laboratories Limited (NYSE:RDY) Q4 2026 Earnings Call Transcript

Dr. Reddy's Laboratories Limited (NYSE:RDY) Q4 2026 Earnings Call Transcript May 12, 2026 Aishwarya Sitharam: Good day, everyone and welcome to the Quarter 4 and Full Year FY '26 Earnings Call of Dr.

Keep Reading →

May 13th, 2026 - News Transcripts

Goldman Sees Limited Upside for Dr. Reddy’s Laboratories Limited (RDY) Amid Generic Drug Concerns

We recently compiled a list of the 10 Best Cancer Stocks to Buy for the Long Term. Dr. Reddy’s Laboratories Limited (NYSE:RDY) is one of the best cancer stocks on our list.

Keep Reading →

May 11th, 2026 - News

10 Best Cancer Stocks to Buy for the Long Term

In this article, we will be taking a look at the 10 Best Cancer Stocks to Buy for the Long Term.

Keep Reading →

May 10th, 2026 - Hedge Funds News

9 Best Indian Stocks to Buy According to Hedge Funds

In this article, we will discuss the 9 Best Indian Stocks to Buy According to Hedge Funds.

Keep Reading →

April 23rd, 2026 - Hedge Funds News

Dr. Reddy's Laboratories Limited (NYSE:RDY) Q3 2026 Earnings Call Transcript

Dr. Reddy's Laboratories Limited (NYSE:RDY) Q3 2026 Earnings Call Transcript January 21, 2026Dr. Reddy's Laboratories Limited reports earnings inline with expectations.

Keep Reading →

January 27th, 2026 - News Transcripts

Dr. Reddy's Laboratories Limited (NYSE:RDY) Q2 2026 Earnings Call Transcript

Dr. Reddy's Laboratories Limited (NYSE:RDY) Q2 2026 Earnings Call Transcript October 24, 2025Dr. Reddy's Laboratories Limited beats earnings expectations.

Keep Reading →

October 28th, 2025 - News Transcripts

Dr. Reddy's Laboratories Limited (NYSE:RDY) Q1 2026 Earnings Call Transcript

Dr. Reddy's Laboratories Limited (NYSE:RDY) Q1 2026 Earnings Call Transcript July 23, 2025Dr. Reddy's Laboratories Limited beats earnings expectations. Reported EPS is $0.2, expectations were $0.18.

Keep Reading →

July 25th, 2025 - News Transcripts